Eucrates Biomedical Acquisition Corp. Unit

10.04+0.0900+0.90%Vol 7911Y Perf -1.00%
Jun 27th, 2022 00:51 DELAYED
BID9.90 ASK10.04
Open9.98 Previous Close9.95
Pre-Market- After-Market-
 - -  - -%
Target Price
- 
Analyst Rating
— — 0.00
Potential %
- 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
25.15 
Earnings Rating
Market Cap103.91M 
Earnings Date
-
Alpha0.00 Standard Deviation0.03
Beta-0.04 

Today's Price Range

9.9810.04

52W Range

9.8310.67

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
0.70%
1 Month
1.21%
3 Months
1.01%
6 Months
0.40%
1 Year
-1.00%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
EUCRU10.040.09000.90
AAPL137.44-4.2200-2.98
GOOG2 251.43-81.0200-3.47
MSFT256.48-8.4100-3.17
XOM91.502.47002.77
WFC40.18-0.0600-0.15
JNJ176.94-5.1800-2.84
FB196.640.99000.51
GE65.88-0.8300-1.24
JPM115.82-0.5600-0.48
Earnings HistoryEstimateReportedSurprise %
----
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume791
Shares Outstanding10.35K
Shares Float10.35M
Trades Count9
Dollar Volume8.00K
Avg. Volume2.17K
Avg. Weekly Volume1.65K
Avg. Monthly Volume1.67K
Avg. Quarterly Volume3.18K

Eucrates Biomedical Acquisition Corp. Unit (NASDAQ: EUCRU) stock closed at 10.04 per share at the end of the most recent trading day (a 0.9% change compared to the prior day closing price) with a volume of 791.0000 shares and market capitalization of 103.91M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Diversified Financial Services industry, Financial Services sector and employs 4 people. Eucrates Biomedical Acquisition Corp. Unit CEO is Parag Saxena.

The one-year performance of Eucrates Biomedical Acquisition Corp. Unit stock is -1%, while year-to-date (YTD) performance is 0.6%. EUCRU stock has a five-year performance of %. Its 52-week range is between 9.83 and 10.665, which gives EUCRU stock a 52-week price range ratio of 25.15%

Eucrates Biomedical Acquisition Corp. Unit currently has a PE ratio of -, a price-to-book (PB) ratio of -, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of 2.99%, a ROC of 3.13% and a ROE of 3.19%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Eucrates Biomedical Acquisition Corp. Unit, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Eucrates Biomedical Acquisition Corp. Unit’s next earnings report date is -.

The consensus rating of Wall Street analysts for Eucrates Biomedical Acquisition Corp. Unit is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Eucrates Biomedical Acquisition Corp. Unit stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Eucrates Biomedical Acquisition Corp. Unit has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Eucrates Biomedical Acquisition Corp. Unit has a Buy technical analysis rating based on Technical Indicators (ADX : 30.11, ATR14 : 0.07, CCI20 : 108.41, Chaikin Money Flow : 0.65, MACD : 0.01, Money Flow Index : 35.63, ROC : 1.62, RSI : 67.93, STOCH (14,3) : 28.32, STOCH RSI : 1.00, UO : 57.97, Williams %R : -71.68), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Eucrates Biomedical Acquisition Corp. Unit in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating-
0.00
-
0.00
-
0.00

Eucrates Biomedical Acquisition Corp. Unit

Eucrates Biomedical Acquisition Corp is a blank check company.

CEO: Parag Saxena

Telephone: +1 212 710-5220

Address: 250 West 55th Street, New York 10019, NY, US

Number of employees: 4

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

54%46%

Bearish Bullish

54%46%

Bearish Bullish

48%52%

News

Stocktwits